Promita Ghosh (she/her)
@ghoshonthemove.bsky.social
Biochemistry PhD student at McGill. Studies and loves talking about RTKs in lung cancer. Coffee and cafe lover. Also, black hole enthusiast.
Reposted by Promita Ghosh (she/her)
Authoritative review from The one and only @ghoshonthemove.bsky.social ☺️on her doctoral work on NSCLC 🫁 @mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers
portlandpress.com/biochemsoctr...
Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...
portlandpress.com
September 10, 2025 at 12:58 PM
Authoritative review from The one and only @ghoshonthemove.bsky.social ☺️on her doctoral work on NSCLC 🫁 @mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers
portlandpress.com/biochemsoctr...
Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers
Why does MET exon 14 skipping matter? It is more than a mere oncogenic mutation!😱🫁
Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond
@mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond
@mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression
The MET receptor tyrosine kinase is a pivotal regulator of cellular survival, motility, and proliferation. Mutations leading to skipping of exon 14 (METΔex14) within the juxtamembrane domain of MET im...
portlandpress.com
September 10, 2025 at 1:45 PM
Why does MET exon 14 skipping matter? It is more than a mere oncogenic mutation!😱🫁
Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond
@mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond
@mcgillgci.bsky.social
portlandpress.com/biochemsoctr...
Reposted by Promita Ghosh (she/her)
Got new #TCR-pMHC data to send our way into BATCAVE? Wanna try BATMAN to predict targets of your #TCR? We would love to hear from you!
💽Database+codes: github.com/meyer-lab-cs...
💻BATMAN software + tutorials: github.com/meyer-lab-cs...
🦇Lets decode TCR-pMHC logic, one mutation at a time🦇
💽Database+codes: github.com/meyer-lab-cs...
💻BATMAN software + tutorials: github.com/meyer-lab-cs...
🦇Lets decode TCR-pMHC logic, one mutation at a time🦇
July 25, 2025 at 3:12 PM
Got new #TCR-pMHC data to send our way into BATCAVE? Wanna try BATMAN to predict targets of your #TCR? We would love to hear from you!
💽Database+codes: github.com/meyer-lab-cs...
💻BATMAN software + tutorials: github.com/meyer-lab-cs...
🦇Lets decode TCR-pMHC logic, one mutation at a time🦇
💽Database+codes: github.com/meyer-lab-cs...
💻BATMAN software + tutorials: github.com/meyer-lab-cs...
🦇Lets decode TCR-pMHC logic, one mutation at a time🦇
Reposted by Promita Ghosh (she/her)
Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer
Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...
www.nature.com
June 3, 2025 at 3:35 PM
Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Promita Ghosh (she/her)
Streptomycin Targets Tumor-Initiating Cells by Disrupting the Oxidative Phosphorylation (OXPHOS) Pathway by Hélène Guillorit, @mariaduca-cnrs.bsky.social, Françoise Macari, Alexandre David et al at @cnrs.fr @inserm.fr http://dlvr.it/TKDrwY
April 18, 2025 at 1:01 PM
Streptomycin Targets Tumor-Initiating Cells by Disrupting the Oxidative Phosphorylation (OXPHOS) Pathway by Hélène Guillorit, @mariaduca-cnrs.bsky.social, Françoise Macari, Alexandre David et al at @cnrs.fr @inserm.fr http://dlvr.it/TKDrwY
Reposted by Promita Ghosh (she/her)
Nature research paper: Generation of human adult hepatocyte organoids with metabolic functions
https://go.nature.com/43WXrX7
https://go.nature.com/43WXrX7
Generation of human adult hepatocyte organoids with metabolic functions - Nature
The combined activation of Wnt and STAT3 signalling enables long-term self-renewal of human hepatocyte organoids, maintaining hepatic identity, supporting gene editing and offering therapeutic potential for liver disease through enhanced functionality, structure and metabolic competency.
go.nature.com
April 18, 2025 at 1:14 PM
Nature research paper: Generation of human adult hepatocyte organoids with metabolic functions
https://go.nature.com/43WXrX7
https://go.nature.com/43WXrX7
Reposted by Promita Ghosh (she/her)
Can blocking “jumping genes” treat diseases and aging?
The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4
The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4
Could blocking ‘jumping genes’ help fight disease and aging?
The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own
scim.ag
April 18, 2025 at 1:32 PM
Can blocking “jumping genes” treat diseases and aging?
The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4
The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4